Bioavailability Clinical Development Drugs Medicine 
Drug Discovery World
DECEMBER 22, 2023
Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex.
Pharmaceutical Technology
AUGUST 30, 2022
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
MAY 23, 2024
Innovations in Skin Cancer Treatment: Precision Medicine and Immunotherapy Treatment options for skin cancer have considerably evolved with a growing emphasis on precision medicine and immunotherapy. Precision medicine allows more effective and personalized treatment plans, which minimizes side effects and improves patient outcomes.
pharmaphorum
NOVEMBER 9, 2022
for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.
The Pharma Data
MARCH 8, 2021
Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related. In addition to the ongoing clinical studies, Merck has conducted a comprehensive nonclinical program to characterize the safety profile of molnupiravir. About Molnupiravir.
The Pharma Data
NOVEMBER 19, 2020
20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov.
Delveinsight
JULY 30, 2020
Key pharma players such as Bluebird Bio , Minoryx Therapeutics , MedDay Pharmaceuticals , Magenta Therapeutics , and others are proactively focusing on developing therapies to address the unmet needs prevailing in the ALD market. The pharma players are evaluating their pipeline candidates in different stages of clinical development.
Expert insights. Personalized for you.
52 
Let's personalize your content